FIELD: medicine.
SUBSTANCE: invention relates to medicine and can be used to correct undifferentiated connective tissue dysplasia in adolescents and adults. To do this, a preparation to normalize the intestinal microflora is taken in therapeutic doses during meals, course intake during the year. Preparation containing strains of propionic acid bacteria that produce biologically active substances, such as vitamin B12, folic acid, amino acids that are actively involved in the process of collagen protein synthesis is taken, with a gradual increase in the dose of the preparation from the initial 1/4 daily dose for 3–4 days to 1/2 daily dose for another 3–4 days with a switch to a daily dose in 7–8 days from the start of the preparation intake. Course of treatment is taken at least twice a year, the duration of the course is two months with a weekly break between the monthly intake of the preparation, and the break between the courses is at least 1–2 months.
EFFECT: invention ensures the inflow of exogenous living microbial cells of the normal intestinal microflora, increasing the production of endogenous factors that improve metabolic processes in the connective tissue, lipid metabolism, and increasing the activity of the body's antioxidant systems.
1 cl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF CORRECTION OF VIOLATIONS OF METABOLIC PROCESSES IN CONNECTIVE TISSUE | 2018 |
|
RU2680389C1 |
METHOD OF UNDIFFERENTIATED CONNECTIVE DISPLASY CORRECTION | 2007 |
|
RU2353377C2 |
METHOD FOR CORRECTION OF NON-DIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA | 2005 |
|
RU2290175C2 |
METHOD FOR TREATMENT OF ADOLESCENTS WITH UNDIFFERENTIATED DYSPLASIA OF CONNECTING TISSUE | 2016 |
|
RU2623451C1 |
METHOD OF AGE-SPECIFIC THERAPY AND PREVENTION OF CONNECTIVE TISSUE DYSPLASIA | 2016 |
|
RU2657751C1 |
METHOD FOR COMPLEX SEQUENTIAL USE OF PATHOGENETIC AGENTS IN TREATMENT IN CHILDREN WITH TUBERCULOSIS INFECTION | 2020 |
|
RU2746642C1 |
METHOD FOR CORRECTING MICROFLORA IN GASTROINTESTINAL TRACT | 2000 |
|
RU2217156C2 |
BIOLOGICALLY ACTIVE AGENT WITH ANTIMUTAGENIC ACTION | 2023 |
|
RU2823630C1 |
METHOD FOR SELECTING TACTICS FOR TREATMENT OF GENITAL PROLAPSE IN PATIENTS WITH UNDIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA | 2017 |
|
RU2682497C1 |
METHOD OF TREATING PATIENTS WITH INTESTINAL DYSBACTERIOSIS | 2009 |
|
RU2400235C1 |
Authors
Dates
2019-02-20—Published
2018-01-09—Filed